Production of more the 600 thousands of Remdesivir vials

Author:
Actoverco
Date:
04 January 2021
41

“Currently, about 6 million people in the country are constantly taking various drugs of Actoverco” said the director of the Actoverco’s factory.

“Currently, about 6 million people in the country are constantly taking various drugs of Actoverco” said the director of the Actoverco’s factory.

According to the public relations of Actover group, Dr. Reza Mostofi, during the visit of Dr. Alireza Zali, Commander of Corona Countermeasures Headquarters in Tehran metropolis, said: “Actoverco pharmaceutical and food industry group currently have 300 pharmaceutical products, 500 food products in 43000 m2 of drug production space and 70000 m2 of food production space and 4200 human resources in this holding.”

 Also, Actoverco department has 18 production lines of tablets and capsules, 3 vial production lines, 2 pre-filled syringe production lines, 1 ampoule production line, 3 lyophilized drugs production lines and 4 production lines with bioreactors. We also have more than 10 GMP certifications for our product lines.

Regarding COVID-19 pandemic, Mostofi added: “Design and supplying medical gowns and producing hand and surface disinfectant solutions and donating them to medical centers and deprived areas; supplying Oseltamivir, Lopinavir/Ritonavir drugs and distributing it throughout the country In April of this year; being the first producer of Remdesivir injectable drug in two forms of solution and lyophilized powder with production of more than 600000 vials; production of Ivermectin; study and research in the field of COVID-19 vaccine production and preparation of infrastructure and industrial phase facilities for this product was some of the taken measures of Actoverco during the COVID-19 pandemic.”

Related Posts

4R4A061511-2048x1365

Atipharmed Supports the 6th International Congress on Minimally Invasive Techniques in Gynecology and Endometriosis

M_HA2443

Scientific Conference on the Effects of Hormone Replacement Therapy (HRT) in Menopause

4R4A3160

Holding the 21st MS Congress of Iran with the participation of Actoverco

M_HA1634

Presentation of Actover’s latest products at the Gastrointestinal and Liver Diseases Congress

4R4A2655-Pano

Introduction of Actoverco Cardiovascular Medications at the 8th International Heart Failure Congress